News Focus
News Focus
Followers 220
Posts 33063
Boards Moderated 1
Alias Born 08/29/2012

Re: None

Tuesday, 11/04/2025 2:24:38 PM

Tuesday, November 04, 2025 2:24:38 PM

Post# of 446516
🔥 ✅️ ELTP Catalyst ✅️ 🔥

✅️✅️✅️ 1. Cash Flow Positive
✅️ 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
✅️✅️ 3. Adderall IR $421.7 Million IMS market Approved and Launched
✅️✅️ 4. Adderall XR $865 Million IMS market Approved and Launched
✅️ 5. Double digit quarterly revenues in millions
✅️ 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
✅️ 7. DEA increases manufacturing quotas for Adderall & Vyvance
✅️ 8. Generic OxyContin - FIRST TO FILE ? FDA Aug 17, 2023 $720 Million
✅️ 9. Generic Vyvanse - $4.3 BILLION - FDA submission Dec 2023
✅️ 10. FDA Acceptance of Generic OxyContin Sept 2023
✅️ 11. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__12. Obtain Full ownership of generic Adderall IR $ 421.7 Million from Mikah
__13. Obtain Full ownership of generic Adderall XR $ 865 Million from Mikah
✅️ 14. Generic Methotrexate Antimetabolite- Approval
✅️ 15. Launch generic Methotrexate $63 Million
✅️ 16. $50+ million in yearly revenues
✅️ 17. Lowest PE ratio for OTC Healthcare sector
✅️ 18. Become the ONLY company showing rapid growth on the OTC while being profitable
✅️ 19. Put Opioids back on the Table- due to reduced risk of opioid litigation
✅️ 20. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
✅️ 21. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
✅️ 22. Generic IR Adderall® Receives Marketing Approval from the Israeli Ministry of Health Oct 2024
✅️ 23. Final Approval of New Manufacturing Facility/Expansion
✅️ 24. Generate revenues over $20 million/quarter
✅️ 25. Generate revenues over $30 million/quarter
✅️ 26. Generate revenues over $40 million/quarter
__ 27. Generate revenues over $50 million/quarter
✅️ 28. Double output of manufacturing and packaging facilities
✅️ 29. Launch approved generic Tylenol with Codeine $47 Million
✅️ 30. Launch approved generic Norco - Hydrocodone acetaminophen IMS $300 Million
✅️ 31. Launch approved generic Percocet - Oxycodone acetaminophen IMS $317 Million
__ 32. Launch approved generic Dolophine - Methadone HCL tablets IMS $30 Million
__ 33. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
✅️ 34. Generic Vyvanse (The Golden Goose) Approval $4.3 Billion
✅️ 35. Agreement with Indian Research and Development Co.(R&D)
__ 36. Positive BE Study for generic Concerta CNS Stimulant $1.16 Billion
✅️ ✅️ 🔥 37. LAUNCH $4.3 Billion Generic Vyvanse Dec 2024
__38. Generic Concerta- FDA submission $1.16 Billion
✅️ 39. Launch Adderall IR in Israel
✅️ 40. Second order of Adderall IR by Israel
✅️ 41. $150+ million revenues a year run rate
__42. Generic OxyContin FDA Approval $720 Million
✅️🚀 43. Accord Pharma prevail over Purdue in Generic OxyContin infringement suit
https://cafc.uscourts.gov/opinions-orders/23-1953.OPINION.12-30-2024_2443222.pdf

https://www.reuters.com/legal/government/us-supreme-court-will-not-hear-purdue-appeal-oxycontin-patent-case-2025-10-06/#:~:text=The%20court%20decided%20not%20to,drug%20designed%20to%20US Oct 06, 2025
__44. Elite prevail over Purdue in Generic OxyContin infringement suit.
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
__45. Launch generic OxyContin $720 Million
__46. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone this was Drug C in SequestOx reformulation trial
__47. Partner for SequestOx Abuse Deterrent Oxycodone
__48. $200 million in yearly revenue
__49. Undisclosed Mikah ANDA(s)
✅️ ✅️ 50. Positive Pivotal BE Undisclosed ANDA JUNE 2025 🔥 $27 Billion Market 🔥 generic anticoagulant
__51. Complete stability testing for $27 Billion anticoagulant
__52. FDA Submission $27 Billion generic anticoagulant
__53. Generic Concerta Launch $1.16 Billion
__54. DollarLand SP
__55. Uplist to NASDAQ exchange
✅️ 56. Receive additional Analyst coverage from Zack’s Investment
✅️✅️✅️🔥 57. Select M&A advisory firm for buyout
✅️ 58. Perform Business Valuation
__59. Buyout offer/s
__60. Buyer Identified
__61. Buyout Vote of Board of Directors
__62. Halt Trading
__63. Shareholder vote on offer
__64. Buyout Closing Completed —$$$$$$$$$$$
__65. 🔥Vegas BABY !!!!! 🔥
Bullish

Second DEA increase of manufacturing quotas for Adderall & Vyvance

ELTP
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News